Harrow, Inc. Common Stock
HROWHarrow, Inc. (HROW) is a medical technology company specializing in the development and commercialization of advanced microneedle-based systems for the delivery of pharmaceuticals, vaccines, and other therapeutics. The company's innovative approaches aim to improve patient care through minimally invasive, pain-free, and efficient drug administration methods. Harrow's products are designed to enhance compliance, reduce administration costs, and expand access to vital treatments.
Company News
Penn Capital Management sold 1.6 million shares of BGC Group in Q3, reducing its stake to $5.9 million, despite the company reporting record quarterly revenue of $736.8 million, up 31% year-over-year.
Harrow Inc. announced the acquisition of Melt Pharmaceuticals, a clinical-stage company developing a non-opioid sedation tablet (MELT-300) for medical procedures. The company plans to submit a New Drug Application to the FDA in 2027, targeting a U.S. launch in 2028.
Harrow plans to acquire Melt Pharmaceuticals for its MELT-300 sedation therapy, a non-opioid sublingual medication designed to provide rapid sedation for medical procedures. The acquisition aims to expand Harrow's procedural sedation market presence and offer an alternative to traditional IV sedation.
Harrow is raising $250 million through senior unsecured notes due in 2030, with plans to repay existing debt and potentially fund future business development opportunities.
Harrow is issuing $250 million in senior unsecured notes due 2030 and entering a new $40 million revolving credit facility with Fifth Third Bank. The company plans to use proceeds to repay existing debt and redeem outstanding senior notes.
